Literature DB >> 34050002

R-Loop-Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin.

Maryam Safari1, Thomas Litman2, Robert W Robey3, Andrés Aguilera4, Arup R Chakraborty3, William C Reinhold3, Agnes Basseville3,5, Lubov Petrukhin1, Luigi Scotto6, Owen A O'Connor7, Yves Pommier3, Antonio T Fojo1, Susan E Bates8.   

Abstract

Histone deacetylase inhibitors (HDACi) induce hyperacetylation of histones by blocking HDAC catalytic sites. Despite regulatory approvals in hematological malignancies, limited solid tumor clinical activity has constrained their potential, arguing for better understanding of mechanisms of action (MOA). Multiple activities of HDACis have been demonstrated, dependent on cell context, beyond the canonical induction of gene expression. Here, using a clinically relevant exposure duration, we established DNA damage as the dominant signature using the NCI-60 cell line database and then focused on the mechanism by which hyperacetylation induces DNA damage. We identified accumulation of DNA-RNA hybrids (R-loops) following romidepsin-induced histone hyperacetylation, with single-stranded DNA (ssDNA) breaks detected by single-cell electrophoresis. Our data suggest that transcription-coupled base excision repair (BER) is involved in resolving ssDNA breaks that, when overwhelmed, evolve to lethal dsDNA breaks. We show that inhibition of BER proteins such as PARP will increase dsDNA breaks in this context. These studies establish accumulation of R-loops as a consequence of romidepsin-mediated histone hyperacetylation. We believe that the insights provided will inform design of more effective combination therapy with HDACis for treatment of solid tumors. IMPLICATIONS: Key HDAC inhibitor mechanisms of action remain unknown; we identify accumulation of DNA-RNA hybrids (R-loops) due to chromatin hyperacetylation that provokes single-stranded DNA damage as a first step toward cell death. ©2021 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34050002      PMCID: PMC8974437          DOI: 10.1158/1541-7786.MCR-20-0833

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   6.333


  66 in total

Review 1.  DNA polymerase beta.

Authors:  Haitham T Idriss; Osama Al-Assar; Samuel H Wilson
Journal:  Int J Biochem Cell Biol       Date:  2002-04       Impact factor: 5.085

2.  Identifying differentially expressed genes using false discovery rate controlling procedures.

Authors:  Anat Reiner; Daniel Yekutieli; Yoav Benjamini
Journal:  Bioinformatics       Date:  2003-02-12       Impact factor: 6.937

Review 3.  Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60.

Authors:  William C Reinhold; Margot Sunshine; Sudhir Varma; James H Doroshow; Yves Pommier
Journal:  Clin Cancer Res       Date:  2015-06-05       Impact factor: 12.531

4.  The DNA damage response acts as a safeguard against harmful DNA-RNA hybrids of different origins.

Authors:  Sonia Barroso; Emilia Herrera-Moyano; Sergio Muñoz; María García-Rubio; Belén Gómez-González; Andrés Aguilera
Journal:  EMBO Rep       Date:  2019-07-24       Impact factor: 8.807

Review 5.  Understanding nucleotide excision repair and its roles in cancer and ageing.

Authors:  Jurgen A Marteijn; Hannes Lans; Wim Vermeulen; Jan H J Hoeijmakers
Journal:  Nat Rev Mol Cell Biol       Date:  2014-07       Impact factor: 94.444

6.  Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines.

Authors:  Jim J Xiao; Ying Huang; Zunyan Dai; Wolfgang Sadée; Jiyun Chen; Shujun Liu; Guido Marcucci; John Byrd; Joseph M Covey; John Wright; Michael Grever; Kenneth K Chan
Journal:  J Pharmacol Exp Ther       Date:  2005-04-15       Impact factor: 4.030

7.  PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Authors:  Paul G Richardson; Robert L Schlossman; Melissa Alsina; Donna M Weber; Steven E Coutre; Cristina Gasparetto; Sutapa Mukhopadhyay; Michael S Ondovik; Mahmudul Khan; Carole S Paley; Sagar Lonial
Journal:  Blood       Date:  2013-08-15       Impact factor: 22.113

8.  Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage.

Authors:  Chiara Conti; Elisabetta Leo; Gabriel S Eichler; Olivier Sordet; Melvenia M Martin; Angela Fan; Mirit I Aladjem; Yves Pommier
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

9.  Romidepsin in the treatment of cutaneous T-cell lymphoma.

Authors:  Salvia Jain; Jasmine Zain
Journal:  J Blood Med       Date:  2011-04-04

10.  Human proteins that interact with RNA/DNA hybrids.

Authors:  Isabel X Wang; Christopher Grunseich; Jennifer Fox; Joshua Burdick; Zhengwei Zhu; Niema Ravazian; Markus Hafner; Vivian G Cheung
Journal:  Genome Res       Date:  2018-08-14       Impact factor: 9.043

View more
  4 in total

Review 1.  Sources, resolution and physiological relevance of R-loops and RNA-DNA hybrids.

Authors:  Eva Petermann; Li Lan; Lee Zou
Journal:  Nat Rev Mol Cell Biol       Date:  2022-04-22       Impact factor: 113.915

2.  A Histone Deacetylase Inhibitor Induces Acetyl-CoA Depletion Leading to Lethal Metabolic Stress in RAS-Pathway Activated Cells.

Authors:  Agnes Basseville; Pierre-Christian Violet; Maryam Safari; Carole Sourbier; W Marston Linehan; Robert W Robey; Mark Levine; Dan L Sackett; Susan E Bates
Journal:  Cancers (Basel)       Date:  2022-05-26       Impact factor: 6.575

Review 3.  Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review.

Authors:  Alejandra Fernandez; Connor O'Leary; Kenneth J O'Byrne; Joshua Burgess; Derek J Richard; Amila Suraweera
Journal:  Front Mol Biosci       Date:  2021-07-07

4.  HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs.

Authors:  Benigno C Valdez; Yago Nieto; Bin Yuan; David Murray; Borje S Andersson
Journal:  Oncotarget       Date:  2022-10-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.